يعرض 741 - 760 نتائج من 8,891 نتيجة بحث عن 'significant ((((gap decrease) OR (we decrease))) OR (mean decrease))', وقت الاستعلام: 0.46s تنقيح النتائج
  1. 741
  2. 742
  3. 743
  4. 744

    Layup muscle synergies. حسب María Benito-de-Pedro (22057468)

    منشور في 2025
    الموضوعات:
  5. 745
  6. 746
  7. 747
  8. 748

    Table 2 - حسب Rosanna Mary Rooney (17595801)

    منشور في 2024
    "…<div><p>Background</p><p>Evidence indicates that criminal behaviour in youth is linked with a range of negative physical, mental, and social health consequences. Despite a global decrease over the last 30 years, youth crime remains prevalent. …"
  9. 749
  10. 750

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX حسب Lihong Wang (14991)

    منشور في 2024
    "…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …"
  11. 751
  12. 752
  13. 753
  14. 754
  15. 755
  16. 756

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  17. 757

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  18. 758

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"
  19. 759
  20. 760